Videos

Explore the disparities in treatment patterns for myelodysplastic syndromes and discover solutions to improve patient outcomes in community settings.

Study reveals alarming treatment gaps in high-risk Myelodysplastic Syndromes, highlighting disparities and adherence issues that impact patient outcomes.

A recent study uncovers disparities in treatment patterns for myelodysplastic syndromes, revealing critical insights into patient outcomes and care access.

Pierre Gholam, MD, examines the limited trial data on treatment for patients with hepatocellular carcinoma (HCC) with worse Child-Pugh scores.

Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, oxaliplatin) management requires careful attention to cytopenia prevention through growth factor use and aggressive diarrhea management with patient education and antidiarrheal medications.

Panelist discusses how the development of nanoliposomal irinotecan led to the NAPOLI-1 trial showing a survival benefit in second-line treatment and subsequently the NAPOLI-3 trial demonstrating the superiority of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, oxaliplatin) over gemcitabine/nab-paclitaxel in first-line metastatic disease.

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.

Binod Dhakal, MD, discusses using a variety of combination therapies as bridging or later-line options for patients with relapsed myeloma.

Overview of Clinical Trial Data A panelist discusses how first-line treatment recommendations are based on 3 pivotal phase 3 randomized trials: PRODIGE 4 (which established FOLFIRINOX superiority over gemcitabine with 11.1 vs 6.8 months overall survival despite higher toxicity), MPACT (showing gemcitabine plus nab-paclitaxel benefit over single-agent gemcitabine with 8.5 vs 6.7 months survival), and the recent NAPOLI-3 (demonstrating NALIRIFOX superiority over gemcitabine plus nab-paclitaxel with 11.1 vs 9.2 months overall survival in over 750 patients across 180 sites).

A panelist discusses how treatment selection for metastatic pancreatic adenocarcinoma involves evaluating multiple factors including genetic and somatic mutations (particularly homologous recombination deficiency [HRD] alterations like BRCA1/2 and PALB2, which favor platinum-based regimens), patient age and performance status, liver function status, and drug metabolism genotype testing such as dihydropyrimidine dehydrogenase (DPD) deficiency screening to avoid severe 5-FU toxicity in rare cases of homozygous variants.

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of Chief Insights in Oncology.

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating CAR T toxicities.

A clinical study reveals talquetamab's effectiveness as a bridging therapy before CAR T-cell treatment for multiple myeloma, enhancing patient outcomes.

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.

Panelist discusses how the landmark ACCORD 11 trial established FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) as superior to gemcitabine for fit, young patients, whereas the MPACT trial demonstrated that gemcitabine plus nab-paclitaxel provided a more tolerable option for older patients with less preserved performance status.

Panelist discusses how CA 19-9 serves as a useful tumor marker for disease monitoring and recurrence detection in patients with pancreatic cancer, though it requires normalization of bilirubin levels for accurate baseline assessment.

IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

A panelist discusses how first-line treatment for metastatic pancreatic cancer depends on performance status. ECOG 0-1 patients receive preferred options like FOLFIRINOX, modified FOLFIRINOX, or the newly FDA-approved NALIRIFOX regimen (which includes liposomal irinotecan for enhanced drug delivery), whereas ECOG 2 patients typically receive gemcitabine plus nab-paclitaxel, and ECOG 3 patients receive palliative care.

A panelist discusses how a man aged 82 years with good performance status presented with unexplained weight loss and abdominal pain, leading to a diagnosis of metastatic pancreatic adenocarcinoma with KRAS G12D and TP53 mutations confirmed through imaging, biopsy, and next-generation sequencing (NGS) testing.

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

Abhinav Agrawal, MD, discusses findings from a multidisciplinary expert panel on endoscopic lung and lymph node biopsies that show how changes in biopsy methods have affected comprehensive biomarker testing in lung cancer.

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Guillermo Garcia-Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic syndrome.

Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including both germline testing for hereditary cancer syndromes and tumor profiling using next-generation sequencing (NGS) assays to identify actionable mutations.

Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing National Comprehensive Cancer Network treatment guidelines that mirror metastatic disease approaches.